FRE logo

Fresenius SE & Co. KGaA Stock Price

XTRA:FRE Community·€26.1b Market Cap
  • 2 Narratives written by author
  • 2 Comments on narratives written by author
  • 87 Fair Values set on narratives written by author

FRE Share Price Performance

€46.31
12.55 (37.17%)
24.7% undervalued intrinsic discount
€61.46
Fair Value
€46.31
12.55 (37.17%)
24.7% undervalued intrinsic discount
€61.46
Fair Value
Price €46.31
Tokyo €61.46
AnalystConsensusTarget €49.61

FRE Community Narratives

Tokyo·
Fair Value €61.46 24.7% undervalued intrinsic discount

First comes the pain, then the money.

6users have liked this narrative
2users have commented on this narrative
16users have followed this narrative
AnalystConsensusTarget·
Fair Value €49.61 6.7% undervalued intrinsic discount

Global Elderly Demand And Biosimilars Will Transform Healthcare

0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative

Recent FRE News & Updates

Fresenius SE KGaA (ETR:FRE) Will Be Hoping To Turn Its Returns On Capital Around

Sep 22
Fresenius SE KGaA (ETR:FRE) Will Be Hoping To Turn Its Returns On Capital Around

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Reasonably Well

Jul 06
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Reasonably Well

Investors Holding Back On Fresenius SE & Co. KGaA (ETR:FRE)

Jun 21
Investors Holding Back On Fresenius SE & Co. KGaA (ETR:FRE)

This Is Why Fresenius SE & Co. KGaA's (ETR:FRE) CEO Compensation Looks Appropriate

May 17
This Is Why Fresenius SE & Co. KGaA's (ETR:FRE) CEO Compensation Looks Appropriate

These Return Metrics Don't Make Fresenius SE KGaA (ETR:FRE) Look Too Strong

Apr 15
These Return Metrics Don't Make Fresenius SE KGaA (ETR:FRE) Look Too Strong

Fresenius SE & Co. KGaA Key Details

€22.3b

Revenue

€16.9b

Cost of Revenue

€5.4b

Gross Profit

€4.3b

Other Expenses

€1.1b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 05, 2025
Earnings per share (EPS)
1.92
Gross Margin
24.28%
Net Profit Margin
4.84%
Debt/Equity Ratio
60.2%

Fresenius SE & Co. KGaA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Good value average dividend payer.

3 Risks
2 Rewards

About FRE

Founded
1912
Employees
176207
CEO
Michael Sen
WebsiteView website
www.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

German Market Performance

  • 7 Days: 2.1%
  • 3 Months: -1.5%
  • 1 Year: 15.1%
  • Year to Date: 13.3%
Over the last 7 days, the market has risen 2.1%, driven by gains of 2.6% in the Industrials sector. The market is up 15% over the last 12 months. Looking forward, earnings are forecast to grow by 17% annually. Market details ›